{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"185.4","value":"231.1"},{"groupId":"OG001","spread":"54.4","value":"186.3"}]}],"title":"First Collection (10 minutes, 25 minutes)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"92.0","value":"248.8"},{"groupId":"OG001","spread":"48.3","value":"172.0"}]}],"title":"Second Collection (15 minutes, 30 minutes)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"Samples for drug concentration analysis were drawn at 10 and 15 minutes into the infusion for participants in the 15-minute infusion group and at 25 and 30 minutes into the infusion for patients in the 30-minute infusion group. The mean and median zoledronic acid concentrations were greater in the 15-minute group than in the 30-minute group at both sampling timepoints.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 15-minute infusion time, but increasing to a 30-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12 weeks.","id":"OG000","title":"15 - Minute Infusion"},{"description":"Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 30-minute infusion time, but increasing to a 45-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12-weeks.","id":"OG001","title":"30 - Minute Infusion"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK) population was analyzed for zoledronic acid concentration. Participants were considered to be in the PK population if they had evaluable PK data.","reportingStatus":"POSTED","timeFrame":"24 months","title":"Zoledronic Acid Concentrations","type":"SECONDARY","unitOfMeasure":"ng/mL"}